Best GLP-1 Providers in Wisconsin (2026)

See by medication

Looking for a specific GLP-1? Browse Wisconsin providers by drug.

About GLP-1s in Wisconsin

Wisconsin allows telehealth GLP-1 prescribing. Wisconsin Medicaid (BadgerCare Plus) covers GLP-1s only for type 2 diabetes.

• •Wisconsin's adult obesity rate is 33.9%
• •BadgerCare Plus restricts GLP-1 coverage to diabetes
• •Milwaukee and Madison are growing Midwest telehealth markets

Top Cities for GLP-1 Treatment in Wisconsin

Telehealth providers ship to all Wisconsin addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Wisconsin GLP-1 clinic directory →

GLP-1 Care Access in Wisconsin: The Numbers

Wisconsin has 359 NPI-registered in-person weight-management clinics across 79 cities — 9 with an obesity-medicine taxonomy, 206 endocrinology, and 147 bariatric — alongside 96 telehealth programs that ship to Wisconsin addresses. The cheapest verified ongoing compounded semaglutide price available to Wisconsin residents is $79/mo (tirzepatide: $104/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Wisconsin

In Q1 2026, Wisconsin Medicaid reimbursed approximately $99,675,328 across 91,266 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Wisconsin cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $199/mo.

For the exact criteria, drug list, and appeal process, read our Wisconsin Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Wisconsin

According to CDC data, 33.9% of Wisconsin adults have obesity (BMI of 30 or higher). This places Wisconsin at #17 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Wisconsin residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions